Varenicline: An alpha;4β2 nicotinic receptor partial agonist for smoking cessation

Journal of Medicinal Chemistry

Volumn 48, Issue 10, 2005, Pages 3474-3477

  Coe, Jotham W ^a   Brooks, Paige R ^a   Vetelino, Michael G ^a   Wirtz, Michael C ^a   Arnold, Eric P ^a   Huang, Jianhua ^a   Sands, Steven B ^a   Davis, Thomas I ^a   Lebel, Lorraine A ^a   Fox, Carol B ^a   Shrikhande, Alka ^a   Heym, James H ^a   Schaeffer, Eric ^a   Rollema, Hans ^a   Lu, Yi ^a   Mansbach, Robert S ^a   Chambers, Leslie K ^a   Rovetti, Charles C ^a   Schulz, David W ^a   Tingley III, F David ^a   O'Neill, Brian T ^a   more..

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAZAPINE; CYTISINE; DOPAMINE; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; UNCLASSIFIED DRUG; VARENICLINE; BENZAZEPINE DERIVATIVE; QUINOXALINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CIGARETTE SMOKING; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; RAT; SMOKING CESSATION; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME; ANIMAL; BRAIN CORTEX; CELL LINE; CHEMISTRY; HUMAN; METABOLISM; METHODOLOGY; OOCYTE; PHYSIOLOGY; RADIOASSAY; SYNTHESIS; XENOPUS LAEVIS;

ANIMALS; BENZAZEPINES; CELL LINE; CEREBRAL CORTEX; HUMANS; NICOTINIC AGONISTS; OOCYTES; QUINOXALINES; RADIOLIGAND ASSAY; RATS; RECEPTORS, NICOTINIC; SMOKING CESSATION; XENOPUS LAEVIS;

EID: 20844441945     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050069n     Document Type: Article

References (57)

1. The "Counterblaste to Tobacco" King James, 1604.
2. (a) Taylor, A. L.; Bettcher, D. W. Bull. World Health Organ. 2000, 78, 920-929.
3. (b) World Health Organization. Reducing risks, promoting healthy life. In The World Health Report; WHO: Geneva, 2002.
4. (a) Ezzati, M.; Lopez, A. D. Estimates of global mortality attributable to smoking in 2000. Lancet 2003, 362, 847-852.
5. (b) Doll, R.; Peto, R.; Boreham, J.; Sutherland, I. Mortality in relation to smoking: 50 years' observations on male British doctors. Br. Med. J. 2004, 328, 1519-1527.
6. Hogg, R. C.; Bertrand, D. Nicotinic receptors as drug targets. Curr. Drug Targets CNS Neurol. Disord. 2004, 3, 123-130.
7. Sargent P. B. The Distribution of Neuronal Nicotinic Acetylcholine Receptors. In Handbook of Experimental Pharmacology: Neuronal Nicotinic Receptors; Clementi, F.; Fornasari, D.; Gotti, C., Eds.; Springer-Verlag: Berlin, Heidelberg, Germany, 2000; Vol. 144, pp 163-192.
8. (a) Picciotto, M. R.; Zoli, M.; Rimondini, R.; Lena, C.; Marubio, L. M.; Pich, E. M.; Fuxe, K.; Changeux, J. P. Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature 1998, 391, 173-177.
9. (b) Watkins, S. S.; Epping-Jordan, M. P.; Koob, G. F.; Markou, A. Blockade of nicotine self-administration with nicotinic antagonists in rats. Pharmacol. Biochem. Behav. 1999, 62, 743-751.
10. (c) Mansbach, R. S.; Chambers, L. K.; Rovetti, C. C. Effects of the competitive nicotinic antagonist erysodine on behavior occasioned or maintained by nicotine: comparison with mecamylamine. Psychopharmacology (Berlin) 2000, 148, 234-242,
11. (d) Cohen, C.; Bergis, O. E.; Galli, F.; Lochead, A. W.; Jegham, S.; Biton, B.; Leonardon, J.; Avenet, P.; Sgard, F.; Besnard, F.; Graham, D.; Coste, A.; Oblin, A.; Curet, O.; Voltz, C.; Gardes, A.; Caille, D.; Perrault, G.; George, P.; Soubrie, P.; Scatton, B. SSR591813, a novel selective and partial α4β2 nicotinic receptor agonist with potential to smoking cessation. J. Pharmacol. Exp. Ther. 2003, 306 (1), 407-420.
12. Tapper, A. R.; McKinney, S. L.; Nashmi, R.; Schwarz, J.; Deshpande, P.; Labarca, C.; Whiteaker, P.; Marks, M. J.; Collins, A. C.; Lester, H. A. Nicotine activation of α4* receptors: Sufficient for reward, tolerance, and sensitization Science 2004, 5, 1029-1032.
13. (a) Di Chiara, G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur. J. Pharmacol. 2000, 393, 295-314.
14. (b) Dani, J. A.; De Biasi, M. Cellular mechanisms of nicotine addiction. Pharmacol. Biochem. Behav. 2001, 70, 439-446.
15. Dependence is accentuated by rapid dopamine release, a factor influenced by the nonoral mode of delivery of the hallmark compounds of abuse, such as cocaine and crack (nasal and smoked, respectively), nicotine (smoked and buccal), and heroin (injection and smoked). Quinn, D. I.; Wodak, A.; Day, R. O. Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users. Clin. Pharmacokinet. 1997, 33 (5), 344-400.
16. (a) Hughes, J. R.; Higgins, S. T.; Bickel, W. K. Nicotine withdrawal versus other drug withdrawal syndromes: similarities and dissimilarities. Addiction 1994, 89, 1461-1470.
17. (b) Malin, D. H. Nicotine dependence: studies with a laboratory model. Pharmacol. Biochem. Behav. 2001, 70, 551-559.
18. Zhu, B. T. Rational design of receptor partial agonists and possible mechanisms of receptor partial activation: A theory. J. Theor. Biol. 1996, 181, 273-291.
19. Fagerstrom K. Clinical treatment of tobacco dependence: the endurance of pharmacologic efficacy. J. Clin. Psychiatry Monograph. 2003, 18, 35-40.
20. For leading reviews in this area, see: (a) Bunnelle, W. H.; Dart, M. J.; Schrimpf, M. R. Design of ligands for the nicotinic acetylcholine receptors: The quest for selectivity. Curr. Med. Chem. 2004, 4, 299-334.
21. (b) Holladay, M. W.; Dart, M. J.; Lynch, J. K. Neuronal Nicotinic Acetylcholine Receptors as Targets for Drug Discovery. J. Med. Chem. 1997, 40, 4169-4194.
22. (c) Glennon, R. A.; Dukat, M. Nicotinic Receptor Ligands. Med. Chem. Res. 1996, 465-486.
23. (a) Marks, M. J.; Farnham, D. A.; Grady, S. R.; Collins, A. C. Nicotinic receptor function determined by stimulation of rubidium efflux from mouse brain synaptosomes. J. Pharmacol. Exp. Ther. 1993, 264, 542-552.
24. Also see (b) Kem, W. R.; Papke, R. L. Actions of anabaseine and DMAB-anabaseine upon neuronal α4β2 and PC12 cell nicotinic receptors. Abstr. Soc. Neurosci. 1992, 18, 1358.
25. (c) Kem, W. R.; Mahnir, V. M.; Papke, R. L.; Lingle, C. J. Anabaseine is a potent agonist on muscle and neuronal alpha-bungarotoxin-sensitive nicotinic receptors. J. Pharmacol. Exp. Ther. 1997, 283, 979-992.
26. (a) Isolation: Partheil, A. Arch. Pharm. (Weinheim, Ger.) 1894, 232, 161.
27. (b) Structure determination: Ing, H. R. J. Chem. Soc. 1932, 2778.
28. Papke, R. L.; Heinemann, S. F. Partial agonist properties of cytisine on neuronal nicotinic receptors containing the β2 subunit. Mol. Pharmacol. 1994, 45, 142-149.
29. Luetje, C. W.; Patrick, J. Nicotinic Receptors are less sensitive to cytisine than acetylcholine J. Neurosci. 1991, 11, 837-845.
30. Scharfenberg, G.; Benndorf, S.; Kempe, G. Cytisin (Tabex®) als medikamentöse Raucherentwöhnungshilfe. Dtsch. Gesundheitsw. 1971, 26, 463-465.
31. Barlow, R. B.; McLead, L. J. Some studies on cytisine and its methylated derivatives. Br. J. Pharmacol. 1969, 35, 161-174.
32. Reavill, C.; Walther, B.; Stolerman, I. P.; Testa, B. Behavioral and pharmacokinetic studies on nicotine, cytisine and lobeline. Neuropharmacology 1990, 29, 619-624.
33. (a) Rose, J. E.; Behm, F. M.; Westman, E. C. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin. Pharmacol. Ther. 1994, 56, 86-99.
34. (b) Rose, J. E. Behm, F. M.; Westman, E. C.; Levin, E. D.; Stein, R. M.; Lane, J. D.; Ripka, G. V. Nicotine-mecamylamine treatment for smoking cessation: the role of precessation therapy. Exp. Clin. Psychopharmacol. 1998, 6, 331-343.
35. (a) O'Neill, B. T. PCT Int. Appl. WO98 18, 798, 1998: Abstr. 1998, 119, 4774k.
36. (b) Marriere, E.; Rouden, J.; Tadino, V.; Lasne, M.-C. Org. Lett. 2000, 2, 1121-1124.
37. (c) Nicolotti, O.; Canu Boido, C.; Sparatore, F.; Carotti, A. Farmaco 2002, 57, 469-478.
38. (d) Canu Boido, C.; Carotti, A. Sparatore, F. Farmaco 2003, 58, 265-277.
39. (a) Mazzocchi, P. H.; Stahly, B. C. Synthesis and pharmacological activity of 2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepines. J. Med. Chem. 1979, 22, 455.
40. (b) Mazzocchi, P. H.; Harrison, A. M. Synthesis and analgetic activity of 1,2,3,4,5,6-hexahydro-1,6-methano-3-benzazocines. J. Med Chem. 1978, 21, 238-240.
41. (a) Brooks, P. R.; Caron, S.; Coe, J. W.; Ng, K. K.; Singer, R. A.; Vazquez, E.; Vetelino, M. G.; Watson Jr., H. H.; Whritenour, D. C.; Wirtz, M. C. Synthesis of 2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepine via oxidative cleavage and reductive amination strategies. Synthesis 2004, 11, 1755-1758.
42. (b) Singer, R. A.; McKinley, J. D.; Barbe, G.; Farlow, R. A. Preparation of 1,5-methano-2,3,4,5-tetrahydro-1H-3-benzazepine via pd-catalyzed cyclization. Org. Lett. 2004, 6, 2357-2360.
43. O'Donnell, C. J.; Singer, R. A.; Brubaker, J. D.; McKinley, J. D. A general route to the synthesis of 1,5-methano- and 1,5-ethano- 2,3,4,5-tetrahydro-1H-3-benzazepines. J. Org. Chem. 2004, 69, 5756-5759.
44. Glennon, R. A.; Ducat, M. Central nicotinic receptor ligands and pharmacophores. Pharm. Acta Helv. 2000, 74, 103-114.
45. Carroll, F. I. Epibatidine structure-activity relationships. Bioorg. Med. Chem. Lett. 2004, 14, 1889-1896.
46. Wright, E.; Gallagher, T.; Sharples, C. G. V.; Wonnacott, S. Synthesis of UB-165: A novel nicotinic ligand and anatoxin-a/ epibatidine hybrid. Bioorg. Med. Chem. Lett. 1997, 7, 2867-2870.
47. (a) Coon, C. L.; Blucher, W. G.; Hill, M. E. Aromatic nitration with nitric acid and trifluoromethanesulfonic acid. J. Org. Chem. 1973, 38, 4243-4248.
48. (b) For an additional related example of dinitration see: Tanida, H.; Ishitobi, H.; Irie, T.; Tsushima, T. Substituent effects and homobenzylic conjugation in benzonorbornen-2(exo)-ylp-bromobenzenesulfonate solvolyses. J. Am. Chem. Soc. 1969, 91, 4512-4520.
49. Tatiana; F.; Barbara; G.; Matilde; M. M.; Gilchrist, T. L.; De Clercq, E. Synthesis and antiviral evaluation of benzimidazoles, quinoxalines and indoles from dehydroabietic acid. Bioorg. Med. Chem. Lett. 2004, 14, 103-112.
50. (a) Ehrlich, J.; Bogert, M. T. Experiments in the veratrole and quinoxaline groups J. Org. Chem. 1947, 12, 522-534.
51. (b) Jones, R. G.; McLaughlin, K. C. 2,3-Pyrazinedicarboxylic acid. Org. Synth. 1963, 4, 824-827.
52. 3H] nicotine to a single class of high affinity sites in rat brain membranes. Mol. Pharmacol. 1986, 29, 448-454.
53. 3H] methylcarbamylcholine in rat brain. Eur. J. Pharmacol. 1994, 253, 261-267.
54. Tested in a general panel of 39 assays at other biological targets, Nova Screen, Hanover, MD. See Supporting Information.
55. Stuhmer, W. Electrophysiological recording from Xenopus oocytes. Methods Enzymol. 1992, 207, 319-339.
56. Dopamine turnover (%) is the ratio of dopamine metabolites/ dopamine = (DOPAC + HVA/dopamine) = (3,4-dihydroxyphenylacetic acid + 3-methoxy-4- hydroxyphenylacetic acid)/dopamine. Determined in male, Sprague Dawley rats, 200-300 g. Tella, S. R.; Ladenheim, B.; Andrews, A. M.; Goldberg, S. R.; Cadet, J. L. Differential reinforcing effects of cocaine and GBR-12909: biochemical evidence for divergent neuroadaptive changes in the mesolimbic dopaminergic system. J. Neurosci. 1996, 16, 7416-7427.
57. Side effects from overexposure to nicotine and other nicotinic agonists include nausea, vomiting, and seizures. The Merck Index, 10th ed.; Merck: Rahway, NJ, 1983; No. 6365.